Bo-Syuan Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bo-Syuan Lin has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Yi-Fang Yang
Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
2 shared publications - Yu-Chan Chang
Department of Biomedical Imagine and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan
2 shared publications - Cheorl-Ho Kim
Molecular and Cellular Glycobiology Unit, Department of Biological Sciences, SungKyunKwan University, Suwon, Gyunggi-Do, 16419, Republic of Korea; Samsung Advanced Institute of Health Science and Technology (SAIHST), Sungkyunkwan University, Seoul, 06351, Republic of Korea
1 shared publication - Chien-Hsiu Li
Department of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan
1 shared publication - Hao-Wen Chuang
Kaohsiung Veterans General Hospital
1 shared publication - Huei-Yu Cai
Department of Biomedicine Imaging and Radiological Science, National Yang Ming Chiao Tung University, Taipei 11121, Taiwan
1 shared publication
Latest Publications
- Open Access
- 13 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15831
Application of Metabolic Reprogramming to Cancer Imaging and Diagnosis
Cellular metabolism governs the signaling that supports physiological mechanisms and homeostasis in an individual, including neuronal transmission, wound healing, and circadian clock manipulation. Various factors have been linked to abnormal metabolic reprogramming, including gene mutations, epigenetic modifications, altered protein epitopes, and their involvement in the development of disease, including cancer. The presence of multiple distinct hallmarks and the resulting cellular reprogramming process have gradually revealed that these metabolism-related molecules may be able to be used to track or prevent the progression of cancer. Consequently, translational medicines have been developed using metabolic substrates, precursors, and other products depending on their biochemical mechanism of action. It is important to note that these metabolic analogs can also be used for imaging and therapeutic purposes in addition to competing for metabolic functions. In particular, due to their isotopic labeling, these compounds may also be used to localize and visualize tumor cells after uptake. In this review, the current development status, applicability, and limitations of compounds targeting metabolic reprogramming are described, as well as the imaging platforms that are most suitable for each compound and the types of cancer to which they are most appropriate.
- 13 December 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (24) , 15831
Open AccessApplication of Metabolic Reprogramming to Cancer Imaging and Diagnosis
Cellular metabolism governs the signaling that supports physiological mechanisms and homeostasis in an individual, including neuronal transmission, wound healing, and circadian clock manipulation. Various factors have been linked to abnormal metabolic reprogramming, including gene mutations, epigenetic modifications, altered protein epitopes, and their involvement in the development of disease, including cancer. The presence of multiple distinct hallmarks and the resulting cellular reprogramming process have gradually revealed that these metabolism-related molecules may be able to be used to track or prevent the progression of cancer. Consequently, translational medicines have been developed using metabolic substrates, precursors, and other products depending on their biochemical mechanism of action. It is important to note that these metabolic analogs can also be used for imaging and therapeutic purposes in addition to competing for metabolic functions. In particular, due to their isotopic labeling, these compounds may also be used to localize and visualize tumor cells after uptake. In this review, the current development status, applicability, and limitations of compounds targeting metabolic reprogramming are described, as well as the imaging platforms that are most suitable for each compound and the types of cancer to which they are most appropriate.
- Open Access
- 30 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10612
Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer
Urothelial cancer is a malignant tumor with metastatic ability and high mortality. Malignant tumors of the urinary system include upper tract urothelial cancer and bladder cancer. In addition to typical genetic alterations and epigenetic modifications, metabolism-related events also occur in urothelial cancer. This metabolic reprogramming includes aberrant expression levels of genes, metabolites, and associated networks and pathways. In this review, we summarize the dysfunctions of glycolytic enzymes in urothelial cancer and discuss the relevant phenotype and signal transduction. Moreover, we describe potential prognostic factors and risks to the survival of clinical cancer patients. More importantly, based on several available databases, we explore relationships between glycolytic enzymes and genetic changes or drug responses in urothelial cancer cells. Current advances in glycolysis-based inhibitors and their combinations are also discussed. Combining all of the evidence, we indicate their potential value for further research in basic science and clinical applications.
- 30 September 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10612
Open AccessCurrent Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer
Urothelial cancer is a malignant tumor with metastatic ability and high mortality. Malignant tumors of the urinary system include upper tract urothelial cancer and bladder cancer. In addition to typical genetic alterations and epigenetic modifications, metabolism-related events also occur in urothelial cancer. This metabolic reprogramming includes aberrant expression levels of genes, metabolites, and associated networks and pathways. In this review, we summarize the dysfunctions of glycolytic enzymes in urothelial cancer and discuss the relevant phenotype and signal transduction. Moreover, we describe potential prognostic factors and risks to the survival of clinical cancer patients. More importantly, based on several available databases, we explore relationships between glycolytic enzymes and genetic changes or drug responses in urothelial cancer cells. Current advances in glycolysis-based inhibitors and their combinations are also discussed. Combining all of the evidence, we indicate their potential value for further research in basic science and clinical applications.